

VYVGART Hytrulo®
(efgartigimod alfa and hyaluronidase-qvfc)

NOW APPROVED FOR SELF-INJECTION

with the new prefilled syringe

It's your CIDP treatment—you
can help call the shots

*I'm hittin' fairways
with the fellas.*

◦ that's living
VYVIDLY™



What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information throughout. Please see full [Prescribing and Patient Information](#) for VYVGART HYTRULO.

A one-of-a-kind treatment, now in your hands



A first for CIDP

A **~20-30 second self-injection**, delivered once weekly with a prefilled syringe, can mean more time in your day for the people and things you love.*

VYVGART Hytrulo—a different approach to treating CIDP



The first major innovation in CIDP treatment in over 30 years†



Works differently than other CIDP treatments, including IVIg, SCIg, PLEX, and steroids



The first and only plasma-free treatment approved by the FDA for CIDP



Ready to take the next step?

Keep reading to learn more, and then talk to your doctor to see if VYVGART Hytrulo is right for you.

*Please see **Patient Information**. Follow appropriate administration steps in the **Instructions for Use**. Monitor for signs and symptoms of an allergic reaction for at least 30 minutes after injection. If an allergic reaction occurs, you should seek medical attention.

†VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors. FcRn=neonatal Fc receptor; IVIg=intravenous immunoglobulin; PLEX=plasma exchange; SCIg=subcutaneous immunoglobulin.

SELECT IMPORTANT SAFETY INFORMATION

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever; have recently received or are scheduled to receive any vaccinations; have any history of allergic reactions; have kidney (renal) problems. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Important Safety Information throughout. Please see full [Prescribing and Patient Information](#) for VYVGART HYTRULO.



We're toasting the perfect end
to the perfect date.

that's living
VYVIDLY™

The effectiveness of VYVGART Hytrulo was established in 2 stages of a clinical study

Stage A

- **Goal:** Identify patients who had **symptom improvements with VYVGART Hytrulo** at 2 consecutive visits. These patients **moved on to stage B**
- **Symptom improvements were measured using 1 of the following:**
 - Arm and leg function (aINCAT)
 - Grip strength
 - Ability to perform 24 daily activities, such as walking, showering, and dressing (I-RODS)
- All 322 patients in stage A received VYVGART Hytrulo

Improved symptoms



~7 out of 10 patients on VYVGART Hytrulo had improvements and moved on to stage B (221 out of 322 patients).

The study included patients who had:

- ✓ Different types of CIDP: typical and atypical (asymmetrical, distal, and pure motor)
- ✓ Never been treated for CIDP
- ✓ Been previously treated for CIDP with IVIg, SCIg, or steroids

aINCAT=adjusted Inflammatory Neuropathy Cause and Treatment; I-RODS=Inflammatory Rasch-built Overall Disability Scale.

SELECT IMPORTANT SAFETY INFORMATION

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant; are breastfeeding or plan to breastfeed. It is not known whether VYVGART HYTRULO will harm your unborn baby. It is not known if VYVGART HYTRULO passes into your breast milk. Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com.

Please see Important Safety Information throughout. Please see full [Prescribing and Patient Information](#) for VYVGART HYTRULO.

VYVGART Hytrulo significantly reduced the risk of CIDP getting worse

Stage B (main part of the study)

- **Main study goal:** From the start of stage B, determine how long **arm and leg function was maintained without getting worse** for patients who received VYVGART Hytrulo, compared to those who were given placebo
- Arm and leg function (aINCAT) was measured every 4 weeks
- 111 patients received VYVGART Hytrulo, and 110 patients were given placebo

Maintained function

Patients who received VYVGART Hytrulo **maintained their level of arm and leg function longer** than those who were given placebo.

Reduced risk of CIDP getting worse

The risk of CIDP getting worse **was 61% lower** for patients taking VYVGART Hytrulo, compared to those who received placebo.



99% of eligible patients chose to be part of an extended safety study and receive VYVGART Hytrulo (226 out of 228 patients)

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO can cause side effects which can be serious, including infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection: fever; chills; frequent and painful urination; cough; pain and blockage of nasal passages; wheezing; shortness of breath; sore throat; excess phlegm; nasal discharge.

Please see Important Safety Information throughout. Please see full [Prescribing and Patient Information](#) for VYVGART HYTRULO.

An established safety profile

When considering treatment, talking to your doctor about the potential benefits and side effects can help you know what to expect.

Most common side effects

- Respiratory tract infection
- Headache
- Urinary tract infection
- Injection site reactions

Infection

VYVGART Hytrulo may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART Hytrulo until your infection is gone.

Allergic reactions (hypersensitivity reactions)

VYVGART Hytrulo can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART Hytrulo injection.

Infusion or injection-related reactions

VYVGART Hytrulo can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART Hytrulo injection.

Please see [Patient Information](#) for signs and symptoms of infection, allergic reactions, and infusion or injection-related reactions.

These are not all the possible side effects of VYVGART Hytrulo. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The safety of VYVGART Hytrulo was evaluated in the largest clinical study in CIDP history.



Considering self-injection with VYVGART Hytrulo?

Ask your doctor if it's right for you.

Looking for more resources?

The VYVGART Hytrulo Education Line can help. Our Health Educators are available 6 days a week (Monday through Saturday, 8 AM to 9 PM ET).

Call 1-833-VYV-CIDP (1-833-898-2437) to speak with an educator.

Self-inject in about 20-30 seconds—one more reason to consider VYVGART Hytrulo*



One injection

It's a single injection delivered under the skin (subcutaneously)—not into a vein.



One needle

Self-inject with the prefilled syringe that contains a single dose of VYVGART Hytrulo.



One time weekly

It's *your* treatment routine—set the same day each week for your self-injection. If you miss an injection, you have a 3-day window to make it up before returning to your dosing schedule.

*Please see **Patient Information**. Follow appropriate administration steps in the **Instructions for Use**. Monitor for signs and symptoms of an allergic reaction for at least 30 minutes after injection. If an allergic reaction occurs, you should seek medical attention.

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO can cause side effects which can be serious, including allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: rash; swelling of the face, lips, throat, or tongue; shortness of breath; hives; trouble breathing; low blood pressure; fainting.

Please see Important Safety Information throughout. Please see full [Prescribing and Patient Information](#) for VYVGART HYTRULO.

A CIDP treatment that can fit your life, not the other way around



The VYVGART Hytrulo prefilled syringe **can go where you go.*** Self-inject wherever you can properly complete the injection—whether at home or a hotel.



You and/or your caregiver will receive in-person **training at home or in your doctor's office** until you're ready to inject on your own. You'll also get a **demonstration kit** to help you practice.



With VYVGART Hytrulo, you can **self-inject**, or a caregiver can do it for you. You can still get your injection from a healthcare professional.

*Please see **Patient Information**. Follow appropriate administration steps and storage and handling guidance in the **Instructions for Use**.

SELECT IMPORTANT SAFETY INFORMATION


VYVGART HYTRULO can cause side effects which can be serious, including infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction: high blood pressure; chills; shivering; chest, stomach, or back pain.

Please see Important Safety Information throughout. Please see full [Prescribing and Patient Information](#) for VYVGART HYTRULO.

CIDP affects every body differently

CIDP is an autoimmune disease, which means that your immune system is mistakenly attacking you instead of protecting you.

In some people with CIDP, the immune system produces **harmful IgG antibodies** that work against you, along with the **IgG antibodies** that work to protect you.



What causes CIDP symptoms

Your nerves have a protective layer around them called **myelin**. Damage to the myelin over time makes it harder for signals to travel quickly along the nerve. That means signals to and from the arms or legs may slow down or, in some cases, be lost completely.

The role of IgG antibodies

Although the complete cause of CIDP is not fully understood, recent studies suggest that, in some people, **harmful IgG antibodies** may be involved in damaging the myelin.

The impact on daily activities

Physical symptoms like muscle weakness, tingling, or numbness can affect your ability to perform daily tasks. Damage to the myelin is why some people experience CIDP symptoms. In some cases, the damage may be debilitating and irreversible.

IgG=immunoglobulin G.

SELECT IMPORTANT SAFETY INFORMATION

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions. These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Important Safety Information throughout. Please see full [Prescribing and Patient Information](#) for VYVGART HYTRULO.

VYVGART Hytrulo is designed differently


VYVGART Hytrulo is specifically designed to cause a reduction in the number of IgG antibodies, including harmful IgG antibodies.

VYVGART Hytrulo has 2 active ingredients: efgartigimod alfa and hyaluronidase (human recombinant), which helps to increase the distribution and absorption of ingredients into the body.



The role of FcRn receptors

When antibodies, including harmful ones, attach to receptors called **FcRn**, their time in the body is extended. Those that don't attach to FcRn receptors are removed by the body.



VYVGART Hytrulo attaches to FcRn receptors

VYVGART Hytrulo, which includes efgartigimod alfa, is designed to attach to FcRn receptors. By keeping some FcRn receptors occupied, more IgG antibodies remain unattached.



Reduction in IgG antibodies

When IgG antibodies, including **harmful IgG antibodies**, cannot attach to an FcRn receptor, they are removed by the body.



[Watch the science behind VYVGART Hytrulo](#)

SELECT IMPORTANT SAFETY INFORMATION

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever; have recently received or are scheduled to receive any vaccinations; have any history of allergic reactions; have kidney (renal) problems. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Important Safety Information throughout. Please see full [Prescribing and Patient Information](#) for VYVGART HYTRULO.



Personalized support throughout your journey

A Nurse Case Manager is here for you

It may feel overwhelming getting started on a new treatment. With My VYVGART Path, you'll have access to resources and one-on-one support.

My VYVGART Path is a patient support program that pairs you with a dedicated Nurse Case Manager (NCM), who can help you navigate insurance, offer resources, talk through your challenges, and more.

If you'll be self-injecting with the VYVGART Hytrulo prefilled syringe, an NCM can also provide additional education and resources on self-injection.

“They really care about who you are and how you're doing. It's more than setting you up.

My VYVGART Path member

There are 2 options to sign up once your doctor has prescribed you VYVGART Hytrulo:



OPTION 1


Visit enrollMVP.com to complete the My VYVGART Path enrollment form.



OPTION 2

Speak with your doctor and ask to be enrolled in My VYVGART Path.

What you can expect



A personalized understanding of your treatment

My VYVGART Path NCMs are knowledgeable about VYVGART Hytrulo and are dedicated to listening to you and answering any questions you may have.



Empowering resources and information

NCMs can support you throughout your treatment journey to help you in following your doctor's treatment plan.



Hands-on help navigating the insurance process

Dealing with insurance can be complicated. An NCM can help answer any questions you have, help you understand the process, and verify what is covered by your insurance.



Helpful information about a co-pay program and financial assistance programs

If you have financial concerns or gaps in insurance coverage for your VYVGART Hytrulo therapy, an NCM is here for you with information and support. They can also help confirm if you're eligible to pay as little as \$0 for VYVGART Hytrulo and related administration costs.

Ready to get on VYVGART Hytrulo?

Talk to your doctor about the VYVGART Hytrulo prefilled syringe for self-injection. Once prescribed, you can enroll in My VYVGART Path and start getting support from an NCM.

IMPORTANT SAFETY INFORMATION

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection or fever.
- have recently received or are scheduled to receive any vaccinations.
- have any history of allergic reactions.
- have kidney (renal) problems.
- are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
 - Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
- are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter

medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

- **Infection.** VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
 - fever
 - chills
 - frequent and painful urination
 - cough
 - pain and blockage of nasal passages
 - wheezing
 - shortness of breath
 - sore throat
 - excess phlegm
 - nasal discharge
- **Allergic reactions (hypersensitivity reactions).** VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
 - rash
 - swelling of the face, lips, throat, or tongue
 - shortness of breath
 - hives
 - trouble breathing
 - low blood pressure
 - fainting

• **Infusion or injection-related reactions.** VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:

- high blood pressure
- chills
- shivering
- chest, stomach, or back pain

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.



A first-of-its-kind CIDP treatment: VYVGART Hytrulo



An innovative approach to CIDP

VYVGART Hytrulo is the first major innovation in CIDP treatment in over 30 years.*



Proven to significantly reduce the risk of CIDP getting worse

Patients taking VYVGART Hytrulo maintained their arm and leg function for longer than those taking placebo.



Now approved: prefilled syringe for self-injection

A ~20-30 second self-injection, once weekly, can mean more time in your day for the people and things you love.†



A dedicated Nurse Case Manager

Once enrolled in the My VYVGART Path Patient Support Program, your NCM can help you navigate insurance, offer resources, talk through your challenges, and more.

*VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.

†Please see **Patient Information**. Follow appropriate administration steps in the **Instructions for Use**. Monitor for signs and symptoms of an allergic reaction for at least 30 minutes after injection. If an allergic reaction occurs, you should seek medical attention.

VYVGART Hytrulo®
(efgartigimod alfa and hyaluronidase-qyfc)

**Ask your doctor if
VYVGART Hytrulo
is right for you**

Download the doctor discussion guide

Taking note of symptoms and their impact on daily life can help you take charge of conversations with your doctor.



Visit
liveVYVIDLY.com
for helpful resources
and information

live
VYVIDLY™

SELECT IMPORTANT SAFETY INFORMATION

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information throughout. Please see full Prescribing and Patient Information for VYVGART HYTRULO.

VYVGART and VYVGART Hytrulo are registered trademarks of argenx.
LIVE VYVIDLY and THAT'S LIVING VYVIDLY are trademarks of argenx.
For U.S. audiences only. ©2025 argenx US-VYV_HYT-24-00020 V3 04/2025

argenx